[
    [
        {
            "time": "",
            "original_text": "【民生医药|公司深度】华兰生物：血制品景气度提升，四价流感疫苗空间百亿元，成长空间充足",
            "features": {
                "keywords": [
                    "华兰生物",
                    "血制品",
                    "景气度提升",
                    "四价流感疫苗",
                    "百亿元空间",
                    "成长空间充足"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【民生医药|公司深度】华兰生物：血制品景气度提升，四价流感疫苗空间百亿元，成长空间充足",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]